1 / 38

Serologic markers in the diagnosis of irritable bowel disease

Serologic markers in the diagnosis of irritable bowel disease. 7 September 2006 Roni J Bollag. To evaluate the utility of serologic markers in the diagnosis of IBD. Background on IBD Current criteria for IBD diagnosis Evidence for serology in IBD Case study at MCG

Roberta
Télécharger la présentation

Serologic markers in the diagnosis of irritable bowel disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serologic markers in the diagnosis of irritable bowel disease 7 September 2006 Roni J Bollag

  2. To evaluate the utility of serologic markers in the diagnosis of IBD • Background on IBD • Current criteria for IBD diagnosis • Evidence for serology in IBD • Case study at MCG • Serology: adjunct or screening tool • Conclusion

  3. IBD • Spectrum of chronic relapsing disorders affecting GI tract • Crohn disease • Ulcerative colitis • Indeterminate colitis • Lifelong disease beginning in youth (15-30) • Prevalence: 15 -20% (North America) • Immunologically mediated disease in genetically susceptible hosts

  4. IBD – consensus criteria • Chief symptom: abdominal pain with altered bowel habits • Rome criteria

  5. IBD - Rome III criteria • Rule out “Alarm” feature

  6. Epidemiology of IBD

  7. UC vs CD

  8. Pathophysiology • Aberrant immune response with loss of tolerance to normal GI flora leading to chronic inflammation of the GI tract • Genetic susceptibility: multifactorial CARD15/NOD2 in Crohn - increased severity: fibrostenotic small bowel • IBD5, DLG5 • Chr 1, 3, 5, 7, 10, 12, 16

  9. Hypothesized Etiologies

  10. Differential Diagnosis

  11. Antibodies in IBD

  12. IBD Serologies • ANCA – antineutrophilic cytoplasmic abx • pANCA, cANCA (Wegener’s) • Atypical pANCA = not myeloperoxidase • ASCA – anti-Saccharomyces cerevisiae abx • IgG, IgA • Increased titers indicates ileal involvement • Antibodies against bacterial antigens (E. coli) • OmpC, Hup-B • I2 (bacterial sequence in CD) • PAB (antibodies to pancreatic antigens) Lee: IBD2006

  13. pANCA • Produced by B-cells in IBD patients • 70% UC patients pANCA positive • 30% Crohn disease pANCA positive • Left sided colonic disease requiring colectomy • Reduced rate of response to anti-TNF Lee: IBD2006

  14. ANCA immunofluorescence

  15. ASCA ELISA • ASCA – anti-Saccharomyces cerevisiae antibody • Usually measured with IgA or IgG • Increased titers indicates ileal involvement • Crohn Disease 50-60%

  16. Serologic associations

  17. Serologic associations

  18. IBD SCREENING TEST • Modified ANCA / ASCA - lowered threshold • Positive test confirmed by higher titer test • 95% non-IBD patients negative (74 patients) • 69% of IBD patients positive (54 patients) • False negatives will continue with symptoms • Positives confirmed with imaging / scoping • Important in indeterminate colitis - pouch Lee: IBD2006

  19. Serology in CD • Prospective study in children with CD • Children with more severe (internal penetrating / stricturing) disease had increased levels of antibodies • Anti-OmpC, anti I2, anti-CBir1,ASCA,

  20. UptoDate

  21. Prometheus

  22. UptoDate – re: Prometheus • accuracy and predictive value in diagnosis of IBD unclear • prevalence of antibodies in patients with a variety of inflammatory diseases affecting the gut not well studied • ASCA present in 50 % of patients with celiac disease • may reflect a non-specific immune response in small bowel disease • ASCA association with cystic fibrosis • at the present time antibody tests should only be used as an adjunct to conventional testing and clinical diagnosis.

  23. Correlations I • P-ANCA+/ASCA-  UC • P-ANCA-/ASCA+  CD • Positive IBD panel modestly increases pre-test probability for IBD • Positivity for multiple serological markers correlates with disease severity • Negative IBD panel has no clinical relevance

  24. Correlations II • Strongest risk factor for IBD is having a relative with disease – good correlation with serology • Possibility as ‘pre-clinical’ markers in familial IBD • Correlation of ASCA levels with increased severity in CD • No correlation between ANCA levels and UC severity

  25. Diagnosis of IBD • IBD was once a diagnosis of exclusion • With symptom-based approach, IBD now a diagnosis of inclusion • Role of serology?

  26. Diagnosis of IBD • History & physical • Radiological evidence • Endoscopy • IBD inclusion – CD vs UC discrimination Pathology

  27. Pathology • Time honored diagnostic criteria for ulcerative colitis are being questioned • Rectal involvement • Contiguous disease • Non-contiguous UC • Rectal sparing, especially in children Lee IBD2006

  28. Pathology • Non-contiguous distribution in UC • Rectal sparing not uncommon (peds) • One colonoscopy with biopsies should not establish the extent of disease • UC skip lesions do not warrant a diagnosis change to Crohn disease Lee: IBD2006

  29. Viewpoints Rutgeerts, Vermeire Hoffenberg, Fidanza, Sauaia Canani et al Lerner, Schoenfeld

  30. The Insurance angle • Position echoed on four insurance policy statements

  31. Case history – RMD request for Prometheus IBD panel • 11-year-old male with weight loss and diarrhea who developed an intra-abdominal abscess • patient underwent a small-bowel resection at an outside institution • per report specimen was not diagnostic for CD • Peds GI unable to scope the patient due to his recent surgery and requested the Prometheus panel in the interim.   • Patient kept in-house; endoscopy after 4 days

  32. Case history – continued • Case deferred for pathology … PATHOLOGY • Specimen A: The findings are suggestive, but not diagnostic of celiac disease. Repeat biopsy after a trial of gluten-free diet may be helpful. • Specimens D-E: While inflammatory bowel disease is a possible cause of the chronic active colitis, the histologic features are not diagnostic of this disease. No granulomas are identified.

  33. Case history – continued • Case sent for Prometheus panel

  34. Case history – conclusion

  35. Differential Diagnosis

  36. Final Dx • It looks like a duck, walks like a duck, quacks like a duck (see comment) Comment: favor duck; correlate with serologies

  37. Bibliography • Bossuyt, X.(2006) Clin. Chem 52:171-181 • Abreu, M.T. (2002) Inflamm Bowel Dis 8:224-6 • Canani, R.B et al. (2006) J Ped Gastroenterol Nutr 42:9-15 • Reumaux. D. et al. (2003) Best Pract Res Clin Gastroenterol 17:19-35 • Dubinsky , M et al. (2006) Am J Gastroenterol 101:360-367 • Ruemmele et al. (1998) Gastroenterology 115:822-829 • Hoffenberg et al. (1999) J. Pediatr. 134:447-452 • Lerner, A., Schoenfeld, Y. (2002) Eur J. Gastroentero Hepat 14:103-105 • Malagelada, J-R (2005) Int J Clin Pract 60:57-63 • Cash, B.D., Chey, W.D. (2004) Aliment Pharmacol Ther 19:1235-1245 • Lee, J.L. (2006) IBD2006 (powerpoint) • Medscape • UptoDate • Harrison’s Principles of Internal Medicine, 15th ed., 2005

More Related